Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Genmab
Company Location: 1253 COPENHAGEN K G7 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for GEN-1055](https://pryzm-maps.s3.us-west-2.amazonaws.com/222current_maps.png)
Countries in Clinic: Spain
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Heart Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GCT1055-01 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2028-05-28 |
|
GCT1055-01 | P2 |
Recruiting |
Heart Cancer |
2028-05-01 |